Compare SXC & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SXC | FDMT |
|---|---|---|
| Founded | 1960 | 2013 |
| Country | United States | United States |
| Employees | 848 | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 555.4M | 515.6M |
| IPO Year | 2011 | 2019 |
| Metric | SXC | FDMT |
|---|---|---|
| Price | $6.27 | $9.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $9.00 | ★ $31.71 |
| AVG Volume (30 Days) | ★ 1.4M | 783.4K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.78% | N/A |
| EPS Growth | N/A | ★ 18.79 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,600,300,000.00 | $85,209,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $70.28 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 10.30 | ★ 230194.60 |
| 52 Week Low | $5.52 | $2.89 |
| 52 Week High | $9.82 | $12.34 |
| Indicator | SXC | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 46.74 | 52.88 |
| Support Level | $6.24 | $8.41 |
| Resistance Level | $6.90 | $9.78 |
| Average True Range (ATR) | 0.21 | 0.65 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 25.74 | 51.85 |
SunCoke Energy Inc operates as an independent producer of coke in the Americas. Its coke is mainly used as a principal raw material in the blast furnace steelmaking process as well as in the foundry production of casted iron. The company operates through two segments: Domestic Coke and Industrial Services. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal-producing, and other manufacturing-based customers. The majority of revenue is derived from the Domestic Coke segment.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).